Q4 2023

Filed Mar 29, 2024 · 10-K · 89 days after period end · 0001493152-24-012049

Q4 2023 · 10-K

Revenue—

Net Income

-$9.33M

no prior Q4 2022 on file

EPS, diluted—

Operating Cash Flowderived-$1,087,215—

Same quarter

no prior Q4 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2023 · filed Mar 29, 2024 · 89 d after period end

Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR